Red Light Holland (TRIP) AI Stock Analysis

• Market Cap: C$6.34M
• Dividend Yield: N/A
• Average Volume (3M): 212.42K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.27
• Revenue Growth: -28.00%
• EPS Growth: 38.46%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 422,531,200
• 10 Day Avg. Volume: 258,444
• 30 Day Avg. Volume: 212,422
• PEG Ratio: -0.09
• Price to Book (P/B): 1.18
• Price to Sales (P/S): 4.99
• P/FCF Ratio: -6.05
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: C$0.01 ▼(-30.00% Downside)
• Action: Downgraded Date: 12/18/25
• Date: Action: Downgraded 12/18/25

The overall stock score of 40 reflects significant financial challenges, including declining revenues and substantial losses. Technical analysis indicates a bearish trend with weak momentum. Valuation metrics are unfavorable, with a negative P/E ratio and no dividend yield, further impacting the stock's attractiveness.

Positive Factors

Low leverage

A debt-to-equity ratio of 0.09 indicates conservative financial leverage, giving the company structural flexibility to fund operations or weather downturns without large interest burdens. This durability supports strategic choices and reduces solvency risk over the medium term.

Regulated Netherlands market footprint

Operating in a legally permitted market gives sustained commercial access and lower regulatory execution risk than illicit markets. A focused Netherlands footprint supports stable revenue channels and scalable production where product legality and distribution frameworks are established.

Product and research orientation

Active investment in product development, research, and education can create durable brand differentiation and higher-margin proprietary offerings. Over months, this capability can help expand addressable market, support regulatory dialogues, and improve long-term customer retention.

Negative Factors

Declining revenue

Material negative revenue growth erodes scale economics and undermines the business model's sustainability. Continued top-line contraction over several quarters constrains reinvestment, weakens bargaining power with distributors, and raises the need for corrective strategy to restore growth.

Severe negative profitability

Deeply negative margins and ROE signal persistent inability to convert sales into profits. Structural unprofitability pressures equity value, limits retained earnings for reinvestment, and suggests ongoing operational inefficiencies that must be addressed to reach sustainable earnings.

Weak cash generation

Negative operating cash flow and declining free cash flow growth indicate cash burn and reliance on external funding. Over a multi-month horizon this raises financing risk, constrains capital expenditures for scale-up, and may force dilution or cost cuts that impair growth prospects.

Red Light Holland Business Overview & Revenue Model

Company Description

Red Light Holland Corp. (TRIP) is a Canadian company focused on the production and distribution of psilocybin truffles, marketed primarily for recreational and therapeutic use. Operating in the emerging psychedelics sector, Red Light Holland aims to provide high-quality, safe, and consistent products to consumers, leveraging a strong brand presence and innovative cultivation methods. The company is also engaged in education and advocacy efforts surrounding responsible use and the potential benefits of psychedelics.

How the Company Makes Money

Red Light Holland generates revenue primarily through the sale of its psilocybin truffles, which are sold in retail locations and online platforms. The company capitalizes on the growing interest in psychedelics for both recreational and therapeutic purposes. Key revenue streams include direct sales to consumers, partnerships with licensed retailers, and potential collaborations with research institutions focused on psychedelics. Additionally, Red Light Holland may benefit from strategic alliances that enhance its distribution channels, marketing efforts, and educational initiatives, all contributing to its overall earnings.

Red Light Holland Financial Statement Overview

Summary

Red Light Holland is facing significant financial challenges, with declining revenues and substantial losses impacting profitability. While the company maintains a low level of debt, its ability to generate returns and positive cash flow is concerning. The financial health of the company is under pressure, requiring strategic improvements to enhance revenue growth and operational efficiency.

Income Statement

Red Light Holland's income statement reveals significant challenges. The company is experiencing negative revenue growth, with a decline of 13.09% in the TTM period. Profitability metrics are concerning, with a negative net profit margin of -77.82% and negative EBIT and EBITDA margins. These figures indicate substantial losses relative to revenue, suggesting operational inefficiencies and high costs.

Balance Sheet

The balance sheet shows a relatively low debt-to-equity ratio of 0.09, indicating conservative leverage. However, the return on equity is negative at -20.30%, reflecting poor profitability and potential challenges in generating returns for shareholders. The equity ratio is not explicitly provided, but the low debt levels suggest a stable capital structure.

Cash Flow

Cash flow analysis highlights negative operating cash flow and free cash flow, with a concerning free cash flow growth rate of -26.30% in the TTM period. The operating cash flow to net income ratio is negative, indicating cash flow challenges. However, the free cash flow to net income ratio is above 1, suggesting that cash flow is somewhat better than net income figures alone might imply.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Mar 2020
Income Statement
Total Revenue	4.07M	4.94M	4.75M	3.95M	110.96K	0.00
Gross Profit	1.41M	1.91M	2.02M	1.71M	19.35K	0.00
EBITDA	-3.90M	-3.35M	-6.58M	-4.32M	-4.61M	0.00
Net Income	-4.25M	-4.04M	-7.63M	-5.40M	-1.64M	-325.17K
Balance Sheet
Total Assets	19.02M	21.22M	24.08M	30.14M	36.30M	3.97M
Cash, Cash Equivalents and Short-Term Investments	10.73M	12.27M	14.17M	18.53M	32.78M	1.96M
Total Debt	581.60K	2.18M	1.72M	1.77M	866.50K	86.77K
Total Liabilities	3.41M	3.87M	3.82M	3.80M	2.24M	5.11M
Stockholders Equity	15.66M	17.35M	20.07M	26.06M	34.06M	-1.14M
Cash Flow
Free Cash Flow	-1.32M	-2.01M	-3.92M	-6.45M	-3.63M	-238.35K
Operating Cash Flow	-1.11M	-1.48M	-3.23M	-4.39M	-3.36M	-238.35K
Investing Cash Flow	-879.42K	-525.40K	-650.43K	-3.17M	-201.55K	-1.80M
Financing Cash Flow	-705.52K	445.17K	-206.95K	-114.16K	32.78M	4.01M

Red Light Holland Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TRIP, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.00 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:TRIP.

Red Light Holland Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MUSH	54 Neutral	C$8.01M	-15.98	-99.55%	―	-26.71%	-988.89%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CWEB	51 Neutral	C$162.61M	-5.33	-109.83%	―	-4.23%	37.33%
CURA	50 Neutral	C$2.41B	-7.01	-27.48%	―	-3.38%	-31.35%
RVV	44 Neutral	C$8.37M	-0.79	-664.21%	―	―	-80.42%
PLTH	42 Neutral	C$71.58M	-0.60	-83.55%	―	2.19%	-91.41%
TRIP	40 Underperform	C$6.34M	-1.44	-23.76%	―	-28.00%	38.46%

Red Light Holland Corporate Events

Red Light Holland Narrows Focus as Q3 Revenue Rises but Profits Tighten

Red Light Holland reported third-quarter 2026 results showing an 8.3% year-over-year revenue increase to $1.27 million, but a 13.7% decline in gross profit and a slightly higher adjusted EBITDA loss of $0.71 million, while cash fell to $9.24 million amid investment in Bitcoin ETFs and high-interest savings vehicles. Management highlighted normalized sales versus the prior quarter, lower G&A expenses, the shutdown of shiitake mushroom production at AEM to focus on near-profitable operations, and progress in psilocybin R&D through its DEA-registered partner Irvine Labs, underscoring a strategic pivot toward an R&D-driven model and active evaluation of M&A from a relatively strong balance-sheet position.

The most recent analyst rating on (TSE:TRIP) stock is a Hold with a C$0.02 price target. To see the full list of analyst forecasts on Red Light Holland stock, see the TSE:TRIP Stock Forecast page.